Latest Press Releases

A competitively priced comprehensive overview of the Dilutables market.

The pick-up in drilling activity in the UK's offshore sector will continue on the back of high oil prices and tax reforms that support gas production and development. The clarification of budget rules related to the decommissioning of defunct infrastructure in the North Sea will sustain a trend of smaller independents or newcomers in search of safe, producing assets taking up the mature assets that existing players have decided to offload. This will slow the rate of decline, especially in UK gas production, though it will still be insufficient to prevent a rise in its import requirement owing to a policy focus on gas in the country's energy mix. The embrace of shale gas, however, presents upside potential, though it is not likely to make a significant contribution to total gas output within our 10-year forecast period to 2022.

Global Markets Direct's new report, "Norway Orthopedic Devices Investment Opportunities, Analysis and Forecasts to 2018" provides key market data on the Norway Orthopedic Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within twelve market categories - Hip Reconstruction, Trauma Fixation, Orthobiologics, Knee Reconstruction, Spinal Surgery, Arthroscopy, Orthopedic Braces and Supports, Orthopedic Bone Cement and Casting Materials, Orthopedic Prosthetics, Cranio Maxillofacial Fixation (CMF), Other Joint Reconstruction and Orthopedic Tools. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

Global Market Direct's pharmaceuticals report, "Pharma Mar, S.A. - Product Pipeline Review - 2012" provides data on the Pharma Mar, S.A.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Merz Pharma GmbH & Co. KGaA - Product Pipeline Review - 2012" provides data on the Merz Pharma GmbH & Co. KGaA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Japan Tobacco Inc. - Product Pipeline Review - 2012" provides data on the Japan Tobacco Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Chemotherapy Induced Pain - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Pain. Chemotherapy Induced Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Other Dermatological Disorders - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Other Dermatological Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Dermatological Disorders. Other Dermatological Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Renal Cell Carcinoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma. Renal Cell Carcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

This report shows the leading Naval Vessels MRO market segments in various regions across the world. Details of top companies active across the global Naval Vessels MRO market are provided, together with market size and forecast 2012-2022 for the main players across those areas.

This report gives a view of the country's thermal energy market and provides forecasts to 2020. This report includes information on thermal (coal, oil and gas) installed capacity and generation. It provides information on key trends, profiles of major industry participants, information on major power plants and analysis of important deals. This along with detailed information on the regulatory framework and key policies governing the industry, provides a comprehensive understanding of the market for thermal power in the country. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's new report, "France Diagnostic Imaging Market Outlook to 2018 - Ultrasound Systems, MRI Systems, Computed Tomography Systems, Nuclear Imaging Equipment, X-Ray Systems, Mammography Equipment and Others" provides key market data on the France Diagnostic Imaging market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within 10 market categories - Angio Suites, Bone Densitometers, C-Arms, Computed Tomography Systems, Contrast Media Injectors, Mammography Equipment, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems and X-ray Systems. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

GlobalData, the industry analysis specialist, has released its latest research, "Petrochemical Industry in the US - Abundant Feedstock Supply from the Shale Reserves to Revive the US Petrochemical Industry". The study comes from the company's petrochemical research group and provides in-depth analysis of the US petrochemicals industry, highlighting major features and explaining how the shale gas revolution is driving its revival. The report gives the historic and forecast demand and production figures and also discusses the feedstock supply scenario. Additionally, it profiles major liquid-rich shale plays in the US and explains the factors encouraging the growth of drilling activities in these shale plays. It has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's research team of industry experts.

Global Market Direct's pharmaceuticals report, "Transgene Biotek Limited - Product Pipeline Review - 2012" provides data on the Transgene Biotek Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Intas Pharmaceuticals Ltd. - Product Pipeline Review - 2012" provides data on the Intas Pharmaceuticals Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Restenosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Restenosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Restenosis. Restenosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Optic Nerve Injury - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Optic Nerve Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Optic Nerve Injury. Optic Nerve Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Molecular Targeting Technologies, Inc. - Product Pipeline Review - 2012" provides data on the Molecular Targeting Technologies, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Influenza A And B Infections - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Influenza A And B Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Influenza A And B Infections. Influenza A And B Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Soft Tissue Sarcoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Soft Tissue Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma. Soft Tissue Sarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

BMI's Turkey Metals Report Q412 examines how the steel industry has performed in the face of external headwinds and warns some segments are facing increased pressure as a result of decreased manufacturing activity in the EU. It examines the latest plant projects and whether output is keeping pace with the ongoing increases in capacity. The report also analyses the investment strategies being employed by the leading players in the Turkish steel industry, as they seek to maximise the growth opportunities offered by the regional market.

BMI View: A challenging political situation - complete with international sanctions imposed on Iran over the past months - will continue to hamper the functioning of the country's healthcare services. While local companies are encouraged by the government to start producing more complex pharmaceuticals, imports will continue to remain crucial for meeting the population's medical needs, even though their viability has come into question over unpaid bills to suppliers. In the meantime, elevated inflation will eat into consumer purchasing power, while the rising budgetary deficit will preclude the government from additional investment into healthcare. Still, we see considerably longer-term potential in the Iranian pharmaceutical and healthcare markets, especially in volume terms.

BMI expects the Bahrain IT market will grow by around 6% in 2012, despite the recent political unrest on the streets of Manama. BMI expects Bahraini consumption of digital lifestyle products such as smartphones and smart TV sets to hold up relatively well in 2012, particularly following recent hikes to public sector salaries. The 15% wage increase for all civil servants in August will certainly help in this regard, as will the ongoing rise in total employment in the private sector. Household spending in Bahrain is forecast to tick higher in 2012 and despite remaining economic uncertainties, increased demand for mobility and lower prices, as well as greater vendor and channel sales flexibility will drive demand, along with a resumption of low single-digit population growth. Demand for new technologies such LED and 3D TV sets and 3G phones and smartphones will also provide growth opportunities.

Core Views Austerity measures imposed by the so-called troika - made up of the EU, the European Central Bank and the International Monetary Fund - as part of the country's EUR78bn bailout programme, will see to it that government and household consumption and investment spending are negative drags on economic growth. While the continued collapse in import growth will mean a positive contribution to real growth from net exports, the persistently weakening external environment presents a key downside risk to our forecast. We expect the re-balancing of the Portuguese economy to continue over the coming years as structural reforms imposed by the IMF and EU shift the economy onto a more sustainable growth path. In turn, we forecast the current account deficit will continue narrowing as the collapse in domestic demand moderates the merchandise trade deficit and continues to expand the services surplus. While we see little scope for foreign direct investment to pick up this year, beyond 2013 we believe that the government's privatisation drive, which has thus far garnered great interest, will bear fruit, thereby easing deficit financing dependence on the ECB. While Portugal is unlikely to experience the same degree of social and political dislocation currently afflicting other bailout countries Greece and Spain, we maintain that the country's political risk profile will continue to gradually deteriorate over the coming years. Driving this degradation will be an increasingly disillusioned population and inter-party wrangling over the degree to which IMF/EU-mandated austerity and reform measures should be implemented. However, given broad-based support for the bailout package across all political parties, we see little scope for politics to derail Portugal's bailout programme. Key Forecast Changes We have revised our forecast for the current account deficit in 2012 from 5.3% of GDP to 3.2% of GDP. This comes as a result of a stronger than anticipated correction of the current account shortfall in 2011 to 6.4% of GDP (we expected 7.1%) owing to the collapse in domestic demand. Risks To Outlook Downside Risks To Growth Forecast: The biggest immediate danger for Portugal is a deepening of the sovereign debt crisis, either for its own government or in another eurozone country, which would depress domestic confidence and external demand. Upside Risks To Long-Term Outlook: At present, we do not envisage long-term real GDP growth rising much above 1.7% in the latter part of our long-term forecasts to 2021. However, we would upgrade our forecasts upon evidence that the government's structural economic reform package is making headway. Furthermore, if the current debate in the eurozone over growth versus austerity turns in French President Francois Hollande's favour, there is the potential for eurozone-wide growth initiatives that could help boost Portugal's economic fortunes.

The depreciation of the value of the Kenyan shilling has resulted in imports, especially those which are priced in US dollars, becoming more expensive. Added costs are being pushed onto consumers in the form of increased retail prices which are further fuelling inflation. Furthermore, the Central Bank of Kenya has raised interest rates in a bid to save the currency, which has reached an all-time low of KES107 to the dollar. This has increased the cost of borrowing in the country and made it...

The developed world has the largest consumer lending markets, but growth is slowing as borrowing takes off in emerging markets. In emerging markets, the story is about moving the unbanked into the financial mainstream through new financial products or the cross-selling of others. A greater desire for luxury goods and major appliances, as well as a greater capacity to spend on such goods, could help to expand the credit infrastructure in those markets.

In the light of rising hygiene awareness, as well as rising disposable incomes in Turkey, the home care industry experienced positive growth in both volume and value terms in 2011. The category saw similar growth in 2011 as in the review period and, as it remains some way off maturity, Turkey promises considerable potential for growth in the forecast period.